Skip to content

Vir Biotechnology, Inc. VIR Ratios & Valuation

FY'25FY'24FY'23FY'22
Profitability
Operating margin-699.2%+92.1pp-791.3%+2.8pp-794%
Net margin-638.9%+64.5pp-703.4%+10.4pp-713.8%
Returns
Return on equity-45.7%-7.6pp-38.1%-4.6pp-33.5%
Return on invested capital-61.8%-12.5pp-49.3%-0.2pp-49%
Efficiency
Asset turnover0.1×0.0×0.0×-0.6×0.7×-0.1×
Liquidity
Current ratio5.5×-3.2×8.7×-0.3×9.1×+4.1×4.9×+0.3×
Leverage
Debt-to-equity0.1×0.0×0.1×0.0×0.1×0.0×0.1×0.0×
Per Share
Book value per share$5.52-34.6%$8.44-28.8%$11.86-23.1%$15.41+43.6%
Valuation
Market capitalization$838.92M-17.0%$1.01B-25.4%$1.35B-59.8%$3.37B-38.5%
Price / sales12.2×-1.4×13.6×-2.1×15.7×+13.6×2.1×-2.9×
Price / book1.1×+0.2×0.9×0.0×0.9×-0.8×1.6×-2.2×

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Vir Biotechnology, Inc.'s profit margins?
Vir Biotechnology, Inc. (VIR) runs a 96.1% gross margin and a -720.8% operating margin, with a -676.0% net margin.
Where do Vir Biotechnology, Inc.'s ratios come from?
Every ratio is computed from Vir Biotechnology, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.